클로자핀 중단의 이유
Reason for Clozapine Discontinuation
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives : Approximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant schizophrenia. Clozapine is underutilized in the management of treatment-resistant schizophrenia. To understand contributing factors, we analyzed the time course and causes of clozapine discontinuations that occurred over a 20-year period in a clinical setting. Methods : The reasons for discontinuation and duration of clozapine treatment from a retrospective database of 138 patients with schizophrenia who had prescribed clozapine at least a month were reviewed, with the motives for discontinuation coded. The causes for termination were analyzed. Results : Over two-thirds of the patient had ceased clozapine. The two most common causes for discontinuation were side-effects (50%), and own decision (30%). Somnolence accounted for 34% of all side-effects induced discontinuations. Hematological problems accounted for 23% of side-effect. The Maximal treatment dose of clozapine was higher in continuation group (442.36 mg) than in discontinuation group (397.26 mg). The CGI-S score when prescribing clozapine last was higher in discontinuation group than in continuous group. The patients who took atypical antipsychotics before clozapine tended to cease clozapine because of side-effects than who took typical agent. Conclusion : Future studies should seek various methods to relieve side-effects of clozapine. Prospective researches using more objective tools are needed to clarify the reason for clozapine discontinuation.
Abstract
Objectives : Approximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant schizophrenia. Clozapine is underutilized in the management of treatment-resistant schizophrenia. To understand contributing factors, we analyzed the time course and causes of clozapine discontinuations that occurred over a 20-year period in a clinical setting. Methods : The reasons for discontinuation and duration of clozapine treatment from a retrospective database of 138 patients with schizophrenia who had prescribed clozapine at least a month were reviewed, with the motives for discontinuation coded. The causes for termination were analyzed. Results : Over two-thirds of the patient had ceased clozapine. The two most common causes for discontinuation were side-effects (50%), and own decision (30%). Somnolence accounted for 34% of all side-effects induced discontinuations. Hematological problems accounted for 23% of side-effect. The Maximal treatment dose of clozapine was higher in continuation group (442.36 mg) than in discontinuation group (397.26 mg). The CGI-S score when prescribing clozapine last was higher in discontinuation group than in continuous group. The patients who took atypical antipsychotics before clozapine tended to cease clozapine because of side-effects than who took typical agent. Conclusion : Future studies should seek various methods to relieve side-effects of clozapine. Prospective researches using more objective tools are needed to clarify the reason for clozapine discontinuation.
참고문헌 (43)
- Levine SZ, "Treatment response trajectories and antipsychotic medications:examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial", Schizophr Res, 137, pp.141~146 (2012)
- Kane J, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine", Arch Gen Psychiatry, 45, pp.789~796 (1988)
- Meltzer HY, "A prospective study of clozapine in treatment-resistant schizophrenia patients. I. Preliminary report", Psychopharmacology, 99, pp.S68~S72 (1989)
- Glick ID, "Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach", J Clin Psychiatry, 72, pp.1616~1627 (2011)
- Lewis SW, "Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia", Schizophr Bull, 32, pp.715~723 (2006)
- McEvoy JP, "Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment", Am J Psychiatry, 163, pp.600~610 (2006)
- Lieberman JA, "Clozapine: Guidelines for clonical management", J Clin Psychiatry, 50, pp.329~338 (1989)
- Wheeler A, "Outcomes for schizophrenia patients with clozapine treatment: how good does it get?", J Psychopharmacol, 23, pp.957~965 (2009)
- Pai NB, "Reason for clozapine cessation", Acta Psychiatr Scand, 125, pp.39~44 (2012)
- Henneen J, "Suicidal risk during treatment with clozapine: a meta-analysis", Schizophr Res, 73, pp.139~145 (2005)
- Howes OD, "Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation", Br J Psychiatry, 201, pp.481~485 (2012)
- Nielsen J, "Optimizing clozapine treatment", Acta Psychiatr Scand, 123, pp.411~422 (2011)
- Meltzer HY, "Clozapine: balancing safety with superior antipsychotic efficacy", Clin Schizophr Relat Psychoses, 6, pp.134~144 (2012)
- Newcomer JW, "Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review", CNS Drugs, 19(Suppl 1), pp.1~93 (2005)
- Tuunainen A, "Newer atypical antipsychotic medication versus clozapine for schizophrenia", Cochrane Database Syst Rev, pp.CD000966~ (2000)
- Fitzsimons J, "A review of clozapine safety", Expert Opin Drug Saf, 4, pp.731~744 (2005)
- Davis MC, "Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients", Acta Psychiatr Scand, 130, pp.30~39 (2014)
- Patel M, "Cross-sectional study of patients perspectives on adherence to antipsychotic medication: depot versus oral", J Clin Psychiatry, 69, pp.1548~1556 (2008)
- Zygmunt A, "Interventions to improve medication adherence in schizophrenia", Am J Psychiatry, 159, pp.1653~1654 (2002)
- Taylor D, "Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-lasting injection", Br J Psychiatry, 94, pp.165~167 (2009)
- Munro J, "Active monitoring of 12,760 clozapine recipients in the UK and Ireland", Br J Psychiatry, 175, pp.576~580 (1999)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Leucht S, "Maintenance treatment with antipsychotic drugs for schizophrenia", Cochrane Database Syst Rev, 5, pp.CD008016~ (2012)
- Kahn RS, "Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial", Lancet, 371, pp.1085~1097 (2008)
- Szymanski SR, "Course of treatment response in first-episode and chronic schizophrenia", Am J Psychiatry, 153, pp.519~525 (1996)
- Ciudad A, "The Schizophrenia Outpatient Health Outcomes (SOHO)study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain", Eur Psychiatry, 23, pp.1~7 (2008)
- Taylor M, "Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study", J Clin Psychiatry, 69, pp.240~245 (2008)
- Hodgson R, "The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire", Hum Psychopharmacol, 20, pp.141~147 (2005)
- Haro JM, "Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia", Eur Psychiatry, 21, pp.41~47 (2006)
- Ciapparelli A, "Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder:a naturalistic 48-month follow-up study", J Clin Psychiatry, 64, pp.451~458 (2003)
- Laker MK, "Long-term outcome with clozapine:comparison of patients continuing and discontinuing treatment", Int Clin Psychopharmacol, 13, pp.75~78 (1998)
- Seabourne A, "The use of clozapine in South Manchester", Psychiatric Bull, 18, pp.618~619 (1994)
- Krivoy A, "Predictors of clozapine discontinuation in patients with schizophrenia", Int Clin Psychopharmacol, 26, pp.311~315 (2011)
- Atkinson JM, "Outcome following clozapine discontinuation: a retrospective analysis", J Clin Psychiatry, 68, pp.1027~1030 (2007)
- Fenton WS, "Determinants of medication compliance in schizophrenia: empirical and clinical findings", Schizophr Bull, 23, pp.637~651 (1997)
- Hudson TJ, "A pilot study of barriers to medication adherence in schizophrenia", J Clin Psychiatry, 65, pp.211~216 (2004)
- Kane J, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine", Arch Gen Psychiatry, 45, pp.789~796 (1988)
- Young C, "Management of the adverse effects of clozapine", Schizophr Bull, 24, pp.381~390 (1998)
- Longden E, "Assessing and reporting the adverse effects of antipsychotic medication: A Systematic Review of clinical studies, and prospective retrospective, and cross-sectional research", Clin Neuropharmacol, 39, pp.29~39 (2016)
- Scheepers FE, "The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics", Neuropsychopharmacol, 24, pp.47~54 (2001)
- Leung JG, "Antipsychotic agents used to augment clozapine during long-term inpatient hospitalizations", Pharmacopsychiatry, 47, pp.263~267 (2014)
- Clarke LA, "Clozapine augmentation with aripiprazole for negative symptoms", J Clin Psychiatry, 67, pp.675~676 (2006)
- Benedetti A, "Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study", Clin Pract Epidemiol Ment Health, 6, pp.30~35 (2010)